AMS gains FDA approval for UroLume Endoprosthesis stent for male urinary obstruction.
This article was originally published in The Gray Sheet
Executive SummaryAMERICAN MEDICAL SYSTEMS UROLUME ENDOPROSTHESIS PMA APPROVAL MAY 6 brings to the U.S. market the first urological stent for treatment of bulbar urethral stricture in males. Pfizer subsidiary AMS says it will launch the stent "soon" through its direct sales force in the U.S. and a combination of direct reps and distributors overseas.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.